Adults aged 40 years or older who have moderate-to-severe plaque psoriasis, may qualify for this clinical research trial and receive either investigational oral treatment (active study drug) or comparator medication.

Eligible participants must have plaque psoriasis covering 10% or more of the total BSA (body surface area), with at least 1 of the following cardiovascular risk factors: current cigarette smoker (vaping does not qualify); diagnosis of hypertension or dyslipidemia; use of blood pressure-lowering or lipid-lowering medications; type 1 or type 2 diabetes; have had heart surgery, cardiac arrest, or stroke; obesity (body mass index ≥ 30 kg/m²); OR family history of heart attacks in a relative younger than 55 or a female immediate family member younger than 65.  Participants will have regular visits with an experienced research team.  

There is no cost to take part, and reasonable study related expenses will be reimbursed.

Individuals will be asked to visit the study centre about 14 times over a period of about 5 years (272 weeks).

Please complete the form below to see if you are eligible for this trial.

If you have any questions/queries regarding this trial please email | [email protected]